ラティッセ(ビマトプロスト)の世界市場2020-2026:医薬品用、化粧品用

QYResearchが発行した調査報告書(QYR20AP01269)
◆英語タイトル:Global Latisse (Bimatoprost) ( CAS 155206-00-1) Industry Research Report, Growth Trends and Competitive Analysis 2020-2026
◆商品コード:QYR20AP01269
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年3月(※2024年版があります。お問い合わせください。)
◆ページ数:114
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:化学・材料
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,087,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,450,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

当リサーチレポートでは、ラティッセ(ビマトプロスト)の世界市場規模が2019年xx百万ドルから2026年xx百万ドルまで年平均xx%成長すると予測しています。当レポートは、ラティッセ(ビマトプロスト)のグローバル市場動向、メーカー別競争状況、種類別市場規模(医薬品用、化粧品用)、用途別市場規模(薬、化粧品、その他)、北米市場、アジア市場、中南米市場、中東・アフリカ市場分析、関連企業情報、サプライチェーン、販売チャネル分析、地域別市場規模予測データなどを掲載しています。

・レポート概要
・グローバル市場動向
・メーカー別競争状況
・ラティッセ(ビマトプロスト)の種類別市場2015-2026:医薬品用、化粧品用
・ラティッセ(ビマトプロスト)の用途別市場2015-2026:薬、化粧品、その他
・ラティッセ(ビマトプロスト)の北米市場分析
・ラティッセ(ビマトプロスト)のアジア市場分析
・ラティッセ(ビマトプロスト)の中南米市場分析
・ラティッセ(ビマトプロスト)の中東・アフリカ市場分析
・関連企業情報:Allergan plc (AbbVie Inc.)、Sandoz(Novartis)、Hi-Tech Pharmacal、Apotex Inc.
・サプライチェーン及び販売チャネル分析
・地域別市場規模予測2021-2026:北米、ヨーロッパ、アジア、中南米、中東・アフリカ
・結論
【レポートの概要】

Bimatoprost is a medication used to treat high pressure inside the eye including glaucoma.Specifically it is used for open angle glaucoma when other agents are not sufficient.It may also be used to increase the size of the eyelashes. It is used as an eye drop.In 2019, the global Latisse (Bimatoprost) ( CAS 155206-00-1) market size was US$ xx million and is forecast to US$ xx million in 2026, growing at a CAGR of xx% during the forecast period. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Latisse (Bimatoprost) ( CAS 155206-00-1).
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Latisse (Bimatoprost) ( CAS 155206-00-1) market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Latisse (Bimatoprost) ( CAS 155206-00-1) market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Latisse (Bimatoprost) ( CAS 155206-00-1) market. Readers of the report can become informed about current and future trends of the global Latisse (Bimatoprost) ( CAS 155206-00-1) market and how they will impact market growth during the forecast period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise and country-wise Latisse (Bimatoprost) ( CAS 155206-00-1) markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E etc.
For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Latisse (Bimatoprost) ( CAS 155206-00-1) market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.
Market Segmentation by Type and by Application
The report includes a detailed analysis of leading and by Type and by Application segments of the global Latisse (Bimatoprost) ( CAS 155206-00-1) market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue, sales analysis and forecast of the global Latisse (Bimatoprost) ( CAS 155206-00-1) market by Type and by Application segment for the period 2015-2026.

Market Segment by Type, the Latisse (Bimatoprost) ( CAS 155206-00-1) market is segmented into
Medicine Grade
Cosmetic Grade

Market Segment by Application, the Latisse (Bimatoprost) ( CAS 155206-00-1) market is segmented into
Medicine
Cosmetic
Others

This report includes the following manufacturers; we can also add the other companies as you want.
Allergan plc (AbbVie Inc.)
Sandoz(Novartis)
Hi-Tech Pharmacal
Apotex Inc.

The study objectives are:
To analyze and research the global Latisse (Bimatoprost) ( CAS 155206-00-1) status and future forecast, involving capacity, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
To present the key Latisse (Bimatoprost) ( CAS 155206-00-1) manufacturers, capacity, production, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Latisse (Bimatoprost) ( CAS 155206-00-1) are as follows:
History Year: 2015-2020
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Research Scope
1.2 Top Latisse (Bimatoprost) ( CAS 155206-00-1) Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Medicine Grade
1.3.3 Cosmetic Grade
1.4 Market Segment by Application
1.4.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Medicine
1.4.3 Cosmetic
1.4.4 Others
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue (2015-2026)
2.1.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue (2015-2026)
2.1.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales (2015-2026)
2.2 Latisse (Bimatoprost) ( CAS 155206-00-1) Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales by Regions (2015-2020)
2.2.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue by Regions (2015-2020)
2.3 Global Top Latisse (Bimatoprost) ( CAS 155206-00-1) Regions (Countries) Ranking by Market Size
2.4 Latisse (Bimatoprost) ( CAS 155206-00-1) Industry Trends
2.4.1 Latisse (Bimatoprost) ( CAS 155206-00-1) Market Top Trends
2.4.2 Market Drivers
2.4.3 Latisse (Bimatoprost) ( CAS 155206-00-1) Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Latisse (Bimatoprost) ( CAS 155206-00-1) Players: Views for Future

3 Competitive Landscape by Manufacturers
3.1 Global Top Latisse (Bimatoprost) ( CAS 155206-00-1) Manufacturers by Sales (2015-2020)
3.1.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales by Manufacturers (2015-2020)
3.1.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Latisse (Bimatoprost) ( CAS 155206-00-1) Sales in 2019
3.2 Global Top Manufacturers Latisse (Bimatoprost) ( CAS 155206-00-1) by Revenue
3.2.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue by Manufacturers (2015-2020)
3.2.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Latisse (Bimatoprost) ( CAS 155206-00-1) as of 2019)
3.4 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Latisse (Bimatoprost) ( CAS 155206-00-1) Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Latisse (Bimatoprost) ( CAS 155206-00-1) Market
3.7 Key Manufacturers Latisse (Bimatoprost) ( CAS 155206-00-1) Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Historic Market Review by Type (2015-2020)
4.1.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Market Share by Type (2015-2020)
4.1.3 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Market Share by Type (2015-2020)
4.1.4 Latisse (Bimatoprost) ( CAS 155206-00-1) Price by Type (2015-2020)
4.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast by Type (2021-2026)
4.2.3 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast by Type (2021-2026)
4.2.4 Latisse (Bimatoprost) ( CAS 155206-00-1) Price Forecast by Type (2021-2026)

5 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Market Size by Application
5.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Historic Market Review by Application (2015-2020)
5.1.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Market Share by Application (2015-2020)
5.1.3 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Market Share by Application (2015-2020)
5.1.4 Latisse (Bimatoprost) ( CAS 155206-00-1) Price by Application (2015-2020)
5.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast by Application (2021-2026)
5.2.3 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast by Application (2021-2026)
5.2.4 Latisse (Bimatoprost) ( CAS 155206-00-1) Price Forecast by Application (2021-2026)

6 North America
6.1 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Company
6.2 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Type
6.3 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Application
6.4 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Countries
6.4.1 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Sales by Countries
6.4.2 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue by Countries
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Company
7.2 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Type
7.3 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Application
7.4 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Countries
7.4.1 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Sales by Countries
7.4.2 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Company
8.2 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Type
8.3 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Application
8.4 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Regions
8.4.1 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Sales by Regions
8.4.2 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Company
9.2 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Type
9.3 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Application
9.4 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Countries
9.4.1 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Sales by Countries
9.4.2 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Type
10.2 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Application
10.3 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Countries
10.3.1 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Sales by Countries
10.3.2 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E

11 Company Profiles
11.1 Allergan plc (AbbVie Inc.)
11.1.1 Allergan plc (AbbVie Inc.) Corporation Information
11.1.2 Allergan plc (AbbVie Inc.) Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Allergan plc (AbbVie Inc.) Latisse (Bimatoprost) ( CAS 155206-00-1) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Allergan plc (AbbVie Inc.) Latisse (Bimatoprost) ( CAS 155206-00-1) Products and Services
11.1.5 Allergan plc (AbbVie Inc.) SWOT Analysis
11.1.6 Allergan plc (AbbVie Inc.) Recent Developments
11.2 Sandoz(Novartis)
11.2.1 Sandoz(Novartis) Corporation Information
11.2.2 Sandoz(Novartis) Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Sandoz(Novartis) Latisse (Bimatoprost) ( CAS 155206-00-1) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Sandoz(Novartis) Latisse (Bimatoprost) ( CAS 155206-00-1) Products and Services
11.2.5 Sandoz(Novartis) SWOT Analysis
11.2.6 Sandoz(Novartis) Recent Developments
11.3 Hi-Tech Pharmacal
11.3.1 Hi-Tech Pharmacal Corporation Information
11.3.2 Hi-Tech Pharmacal Business Overview and Total Revenue (2019 VS 2018)
11.3.3 Hi-Tech Pharmacal Latisse (Bimatoprost) ( CAS 155206-00-1) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 Hi-Tech Pharmacal Latisse (Bimatoprost) ( CAS 155206-00-1) Products and Services
11.3.5 Hi-Tech Pharmacal SWOT Analysis
11.3.6 Hi-Tech Pharmacal Recent Developments
11.4 Apotex Inc.
11.4.1 Apotex Inc. Corporation Information
11.4.2 Apotex Inc. Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Apotex Inc. Latisse (Bimatoprost) ( CAS 155206-00-1) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Apotex Inc. Latisse (Bimatoprost) ( CAS 155206-00-1) Products and Services
11.4.5 Apotex Inc. SWOT Analysis
11.4.6 Apotex Inc. Recent Developments

12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Channels
12.2.2 Latisse (Bimatoprost) ( CAS 155206-00-1) Distributors
12.3 Latisse (Bimatoprost) ( CAS 155206-00-1) Customers

13 Estimates and Projections by Regions (2021-2026)
13.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast (2021-2026)
13.1.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast by Regions (2021-2026)
13.1.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast (2021-2026)
13.2.2 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast (2021-2026)
13.2.3 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast (2021-2026)
13.3.2 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast (2021-2026)
13.3.3 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast (2021-2026)
13.4.2 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast (2021-2026)
13.5.2 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast (2021-2026)
13.5.3 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Size Forecast by County (2021-2026)

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

...

【掲載企業】

Allergan plc (AbbVie Inc.)、Sandoz(Novartis)、Hi-Tech Pharmacal、Apotex Inc.

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ ラティッセ(ビマトプロスト)の世界市場2020-2026:医薬品用、化粧品用(Global Latisse (Bimatoprost) ( CAS 155206-00-1) Industry Research Report, Growth Trends and Competitive Analysis 2020-2026)]についてメールでお問い合わせはこちらでお願いします。